InsidersTradesSigma
Follow the Soleno Therapeutics INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Soleno Therapeutics INC has logged 146 reports. Market capitalisation: €2.8bn. The latest transaction was filed on 31 March 2026 (Cession). Among the most active insiders: Hirano Patricia C. All data is accessible without an account.
146
Insider Decl.
n/a
Thresholds
€737,266
13 ops.
Buy Volume
€92m
61 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Soleno Therapeutics INC Hold (neutral), based on 5 analysts. Average price target: US$53.00.
36Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,464 of 29,063 companies
60.2
score / 100
Value43
Quality78
FCF yld1.7%
Earn yld0.7%
EV/EBITDA·
ROE26%
Gross mgn99%
Net mgn11%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 March 2026
Declarations146 total
4,256 shares@ US$30.03756.4% of flowCommon StockSEC:0002019992-26-000002:0
1,838 shares@ US$31.038425.2% of flowCommon StockSEC:0002019992-26-000002:1
488 shares@ US$31.71876.8% of flowCommon StockSEC:0002019992-26-000002:2
4,864 shares@ US$30.03752.9% of flowCommon StockSEC:0001752631-26-000002:0
2,100 shares@ US$31.038423.6% of flowCommon StockSEC:0001752631-26-000002:1
558 shares@ US$31.71876.4% of flowCommon StockSEC:0001752631-26-000002:2
39,200 shares0Common StockSEC:0001873522-26-000007:0
10,400 shares0Common StockSEC:0002019992-26-000001:0
4,100 shares0Common StockSEC:0001978048-26-000001:0
3,500 shares0Common StockSEC:0001819690-26-000002:0
10,400 shares0Common StockSEC:0001766042-26-000001:0
28,600 shares0Common StockSEC:0001752631-26-000001:0
10,400 shares0Common StockSEC:0001643441-26-000001:0
114,200 shares0Common StockSEC:0001614821-26-000001:0
28,600 shares0Common StockSEC:0001422484-26-000001:0
812 shares@ US$49.9515.0% of flowCommon StockSEC:0002019992-25-000003:0
904 shares@ US$49.952.5% of flowCommon StockSEC:0001766042-25-000003:0
1,922 shares@ US$49.9525.5% of flowCommon StockSEC:0001752631-25-000004:0
904 shares@ US$49.953.9% of flowCommon StockSEC:0001643441-25-000003:0
7,620 shares@ US$49.953.7% of flowCommon StockSEC:0001614821-25-000005:0
2,013 shares@ US$49.956.0% of flowCommon StockSEC:0001422484-25-000003:0
14,286 shares0Common StockSEC:0001819690-25-000008:0
16,071 shares0Common StockSEC:0001978048-25-000003:0
10,046 shares0Common StockSEC:0001408502-25-000008:0
3,830 shares@ US$82.7618.0% of flowCommon StockSEC:0001415889-25-019336:0
25 of 146 declarations
关于 Soleno Therapeutics INC
Soleno Therapeutics Inc. (NASDAQ: SLNO) 是一家总部位于加利福尼亚州雷德伍德城的美国生物制药公司。对于讲法语的投资者来说，Soleno 最好被理解为一家罕见病专家，其股权故事围绕着从临床/监管执行转向商业化展开。该公司此前以 Capnia, Inc. 的名义运营，并于 2017 年更名为 Soleno Therapeutics，这突显了其战略重心转向更专注的罕见病平台。（[stockanalysis.com](https://stockanalysis.com/stocks/slno/company/?utm_source=openai)) Soleno 的核心业务是开发和商业化罕见病的新型疗法，特别侧重于具有严重未满足医疗需求的疾病。其主要资产 VYKAT XR 是投资案例的核心，也是公司从开发阶段生物技术公司转型为具有商业抱负的公司的关键驱动力。在其 2024 年年度报告中，Soleno 将自己描述为一家专注于罕见病的生物制药公司，并指出已剥离原有业务，以专注于这一核心使命。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai)) 从竞争角度来看，Soleno 在一个高度专业化的利基市场中运营，该市场的可寻址患者群体很小，但临床差异化可能具有重要的经济意义。在罕见病领域，成功不仅取决于监管批准：商业化质量、报销可及性、医生认知和上市后执行都至关重要。这使得 Soleno 的市场定位是专注的专家，而非广泛多元化的制药公司。这个机会之所以具有吸引力，正是因为进入壁垒高，而且成功产品的价值相对于公司规模而言可能非常可观。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai)) 从地理上看，Soleno 是一家美国公司，其运营和公司总部位于加利福尼亚州，并在纳斯达克上市，这使其在美国生物技术投资者和事件驱动型市场参与者中具有知名度。对于法国、比利时和瑞士的投资者来说，这意味着 SLNO 应被视为一家在美国上市的医疗保健公司，具有 SEC 注册人的报告深度和小型生物技术公司向商业化转型时典型的波动性特征。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/0000950170-25-029545-index.html?utm_source=openai)) 最近的发展主要集中在公司围绕 VYKAT XR 的监管和商业进展。Soleno 的 2024 年 SEC 文件强调了 FDA 接受 NDA、优先审查指定以及 PDUFA 目标日期为 2024 年 12 月 27 日，这标志着其上市之路上的一个重要里程碑。更广泛地说，最近的市场报道表明，投资者越来越多地将 Soleno 视为一个与主要罕见病资产相关的商业化故事，而非纯粹的临床阶段开发商。对于股票分析师而言，关键的监测点仍然是产品采用、支付方可及性、监管后续行动以及上市轨迹的持久性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai))
